• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

完全切除的非小细胞肺癌患者的长期随访结果。

Results of long-term follow-up of patients with completely resected non-small cell lung cancer.

机构信息

Department of Thoracic Surgery, Tohoku University Hospital, Sendai, Japan.

出版信息

Ann Thorac Surg. 2012 Apr;93(4):1061-8. doi: 10.1016/j.athoracsur.2012.01.004. Epub 2012 Mar 3.

DOI:10.1016/j.athoracsur.2012.01.004
PMID:22386090
Abstract

BACKGROUND

In patients with completely resected non-small cell lung cancer, recurrence-free survival, postrecurrence survival, and metachronous primary lung cancer have not been well studied at the same time.

METHODS

A total of 315 patients with non-small cell lung cancer who underwent complete resection between 2001 and 2005 were examined. Patients were routinely assessed with computed tomography of the chest and physical checkups every 4 months for the first 2 years and every 6 months from the third to the fifth year. After that, they were examined annually.

RESULTS

The overall 5-year survival was 70%. Of all 315 patients, 107 had recurrent disease. The median recurrence-free survival was 15.7 months. Multivariate analysis showed that pathologic stage and pleural invasion were associated with decreased recurrence-free survival. The median postrecurrence survival was 18.7 months. Multivariate analysis indicated that male sex, pleural invasion, extrathoracic recurrence, and supportive care for recurrence were associated with decreased postrecurrence survival. The cumulative rate of metachronous primary lung cancer at 5 years was 3.7%, and it developed even 8 years after the initial operation.

CONCLUSIONS

Only pleural invasion of the original lung cancer was related to both recurrence-free survival and postrecurrence survival. Moreover, postrecurrence survival was related to both site and treatment of the initial recurrence. The incidence of metachronous primary lung cancer was stable over time after the initial operation.

摘要

背景

在完全切除的非小细胞肺癌患者中,无复发生存、复发后生存和同时性原发性肺癌尚未得到很好的研究。

方法

共检查了 315 例 2001 年至 2005 年间行完全切除术的非小细胞肺癌患者。患者在最初的 2 年内每 4 个月进行一次胸部 CT 和体格检查,从第 3 年到第 5 年每 6 个月进行一次,之后每年进行一次。

结果

总体 5 年生存率为 70%。在所有 315 例患者中,107 例出现疾病复发。无复发生存的中位时间为 15.7 个月。多变量分析表明,病理分期和胸膜侵犯与无复发生存时间缩短有关。复发后生存的中位时间为 18.7 个月。多变量分析表明,男性、胸膜侵犯、胸外复发和对复发的支持性治疗与复发后生存时间缩短有关。5 年内同时性原发性肺癌的累积发生率为 3.7%,甚至在初始手术后 8 年也会发生。

结论

只有原发性肺癌的胸膜侵犯与无复发生存和复发后生存有关。此外,复发后生存与初始复发的部位和治疗有关。在初始手术后,同时性原发性肺癌的发生率随时间保持稳定。

相似文献

1
Results of long-term follow-up of patients with completely resected non-small cell lung cancer.完全切除的非小细胞肺癌患者的长期随访结果。
Ann Thorac Surg. 2012 Apr;93(4):1061-8. doi: 10.1016/j.athoracsur.2012.01.004. Epub 2012 Mar 3.
2
Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival.完全切除的N1期非小细胞肺癌:影响复发和长期生存的因素
J Thorac Cardiovasc Surg. 2006 Sep;132(3):499-506. doi: 10.1016/j.jtcvs.2006.04.019. Epub 2006 Jul 28.
3
Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection.全肺切除术后复发性非小细胞肺癌的生存情况。
Ann Thorac Surg. 2007 Feb;83(2):409-17; discussioin 417-8. doi: 10.1016/j.athoracsur.2006.08.046.
4
Postrecurrence survival in patients with stage I non-small cell lung cancer.I期非小细胞肺癌患者复发后的生存情况
Eur J Cardiothorac Surg. 2008 Sep;34(3):499-504. doi: 10.1016/j.ejcts.2008.05.016. Epub 2008 Jun 25.
5
Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.完全切除的非小细胞肺癌复发后预后良好患者亚组的鉴定。
Ann Surg Oncol. 2014 Aug;21(8):2546-54. doi: 10.1245/s10434-014-3630-9. Epub 2014 Mar 17.
6
Prognostic value of visceral pleural invasion in resected non-small cell lung cancer diagnosed by using a jet stream of saline solution.使用盐溶液喷射流诊断的切除非小细胞肺癌中脏层胸膜侵犯的预后价值
J Thorac Cardiovasc Surg. 2004 Jun;127(6):1587-92. doi: 10.1016/j.jtcvs.2004.02.001.
7
Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients.预测完全切除的非小细胞肺癌患者复发后的生存期。
Ann Thorac Surg. 2006 Mar;81(3):1021-7. doi: 10.1016/j.athoracsur.2005.09.020.
8
Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size.肿瘤大小为1厘米或更小的非小细胞肺癌患者的长期生存和复发情况
J Thorac Cardiovasc Surg. 2006 Dec;132(6):1382-9. doi: 10.1016/j.jtcvs.2006.08.053. Epub 2006 Oct 30.
9
Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis.完全切除的 I 期非小细胞肺癌伴远处转移患者的复发后生存的预后因素。
Thorax. 2010 Mar;65(3):241-5. doi: 10.1136/thx.2008.110825.
10
Is surgical resection indicated for a solitary non-small cell lung cancer recurrence?手术切除适用于孤立性非小细胞肺癌复发吗?
J Thorac Cardiovasc Surg. 2006 Apr;131(4):838-42. doi: 10.1016/j.jtcvs.2005.11.028.

引用本文的文献

1
Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.表皮生长因子受体阳性非小细胞肺癌患者术后复发的预后影响。
Cancer Rep (Hoboken). 2024 Sep;7(9):e70004. doi: 10.1002/cnr2.70004.
2
Correlation Between the Number of Pathological Risk Factors and Postoperative Prognosis in Patients with Stage I Lung Adenocarcinoma.Ⅰ期肺腺癌患者病理危险因素数目与术后预后的相关性。
Ann Surg Oncol. 2024 Dec;31(13):9310-9320. doi: 10.1245/s10434-024-16045-7. Epub 2024 Aug 19.
3
Effect of initial recurrence site on the prognosis of different tissue types of non-small cell lung cancer: a retrospective cohort study.
初始复发部位对不同组织学类型非小细胞肺癌预后的影响:一项回顾性队列研究。
World J Surg Oncol. 2023 Nov 21;21(1):360. doi: 10.1186/s12957-023-03252-x.
4
Preoperative predictors for recurrence sites associated with poor post-recurrence survival after surgery of non-small cell lung cancer: a multicenter study.非小细胞肺癌手术后与不良复发后生存相关的复发部位的术前预测因素:一项多中心研究。
BMC Cancer. 2023 Nov 6;23(1):1064. doi: 10.1186/s12885-023-11582-y.
5
Wedge resection vs. segmentectomy for lung cancer measuring ≤ 2 cm with consolidation tumor ratio > 0.25.对于实性肿瘤比例>0.25且直径≤2 cm的肺癌,楔形切除术与肺段切除术的比较
Front Oncol. 2023 Aug 28;13:1253414. doi: 10.3389/fonc.2023.1253414. eCollection 2023.
6
Survival and quality-of-life outcomes in early-stage NSCLC patients: a literature review of real-world evidence.早期非小细胞肺癌患者的生存及生活质量结局:真实世界证据的文献综述
Lung Cancer Manag. 2023 Jul 12;12(3):LMT60. doi: 10.2217/lmt-2023-0003. eCollection 2023 Sep.
7
Beyond the Frontline: A Triple-Line Approach of Thoracic Surgeons in Lung Cancer Management-State of the Art.前线之外:胸外科医生在肺癌管理中的三线方法——最新进展
Cancers (Basel). 2023 Aug 9;15(16):4039. doi: 10.3390/cancers15164039.
8
Examination of the effectiveness of local therapy for oligo-recurrence of EGFR-mutated NSCLC.检查局部治疗对 EGFR 突变型 NSCLC 寡复发的效果。
Thorac Cancer. 2023 Mar;14(8):766-772. doi: 10.1111/1759-7714.14805. Epub 2023 Jan 31.
9
Prognostic factors for recurrence in patients with surgically resected non-small cell lung cancer.手术切除的非小细胞肺癌患者复发的预后因素。
Contemp Oncol (Pozn). 2022;26(3):239-246. doi: 10.5114/wo.2022.120638. Epub 2022 Oct 24.
10
Clinical Value of Surveillance F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy.监测¹⁸F-氟脱氧葡萄糖PET/CT在检测非小细胞肺癌根治性治疗后未被怀疑的复发或第二原发性癌症中的临床价值
Cancers (Basel). 2022 Jan 27;14(3):632. doi: 10.3390/cancers14030632.